GSK (NYSE:GSK – Get Free Report) is projected to announce its earnings results before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of $0.44 per share and revenue of $7.75 billion for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.
GSK Trading Down 0.4 %
NYSE GSK opened at $35.20 on Monday. GSK has a 12 month low of $31.72 and a 12 month high of $45.92. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The stock has a 50 day moving average of $34.07 and a 200-day moving average of $37.68. The company has a market cap of $72.96 billion, a PE ratio of 22.86, a PEG ratio of 1.37 and a beta of 0.63.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the stock. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and decreased their price objective for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. StockNews.com downgraded GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 21st. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Six investment analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, GSK presently has an average rating of “Moderate Buy” and a consensus price target of $43.25.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Read More
- Five stocks we like better than GSK
- The Most Important Warren Buffett Stock for Investors: His Own
- 3 Stocks to Gain From Trump’s Return-to-Office Mandate
- Insider Trading – What You Need to Know
- Crane Stock Soars, But the Best Could Be Yet to Come: Here’s Why
- Stock Dividend Cuts Happen Are You Ready?
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
